The level of circulating prolactin is concerned with the induction and growth of mammary tumours in mice and rats (Furth & Clifton 1957 , Muhlbock & Boot 1959 , Pearson et a!. 1969 . Three strains of rats in our laboratories with differing incidences of mammary tumours induced by 7,12 dimethylbenzanthracene (DMBA) were investigated by estimating circulating prolactin at 50 days of age during dicestrus. The strain of rats with the highest incidence of tumours had significantly higher mean circulating prolactin levels than the other two strains (Fig 1) .
Evidence regarding plasma prolactin concentrations in human breast cancer is less exact. We have had experience of two radioimmunoassays, from each strain of dkestrus in three strains ofrat one heterologous , Forrest 1972 and the other homologous. The results of the latter only are reported in this paper. This assay uses a rabbit antihuman amniotic prolactin serum and iodinated human prolactin (kindly supplied by Dr U J Lewis) .
Untreated Breast Cancer
A single blood sample was taken at the same time each day from 84 patients admitted to hospital not receiving any drug known to stimulate prolactin secretion. Forty-five of these patients had breast cancer, 14 primary and 31 advanced; 39 were hospital controls without breast cancer or other malignant disease. Plasma was stored at -20°C and the assay performed in batches. Mean plasma prolactins in milli ampoules/ml (mAmp/ml) of the MRC standard ampoule (71/222) were 8.3+1.2 for the controls, 10.9± 2.2 for the primary and 8.2±0.9 for the advanced group.
Six additional patients with breast cancer who were on various drugs were also studied. Two were receiving phenothiazines, 2 methyldopa and 1 each stilbcestrol and norethisterone. The circulating prolactin levels ranged from 50 to 100 mAmp/ml.
Effect ofStilbastrol
Prolactin estimations were performed in patients with advanced breast cancer before and at one and three months after the start of therapy with oral stilbeestrol 15 mg daily. In all, plasma prolactin rose during the first month and remained elevated after three months. Two of these patients had an objective remission of their disease. Intravenous injections of stilboestrol diphosphate, 500 mg daily, produced a profound increase in prolactin which was maintained for at least 24 hours.
Pituitary Ablation Three patients were studied before and following 90yttrium implantation of the pituitary. The plasma prolactin fell within, seventy-two hours and in 2 patients subsequent estimations revealed barely recordable levels. In the third patient significant concentrations of prolactin remained.
It is known that chlorpromazine increases prolactin secretion in man (Turkington 1972 Prolactin Dependence in Human Breast Cancer Continuing to apply the methodology described in detail elsewhere (Salih, Flax & Hobbs 1972; Salih, Flax, Brander & Hobbs 1972) , the breast cancer tissues from 100 women have to date been studied after being in tissue culture for twentyfour hours, with or without added hormones. Six patterns have emerged: in vitro independence (48 %), or dependence on cestrogen only (11 %), prolactin only (15 %), androgen only (11 %), both prolactin and cestrogen (10%) or both prolactin and androgen (6%). Prolactin dependence has therefore been demonstrated in vitro in 31 % of patients; it is commonest before the menopause (50 %), falling at and soon after menopause (24 %) to 32% of those more than five years since the menopause.
Dose-response evaluations indicate that 8 % of women show dependence at prolactin concentrations in the tissue culture fluid at the lower limit of normal for women (6 ng/ml). A hypophysectomy would need to be very good to abrogate such levels, perhaps explaining why Joplin (1965) assessed good responses to such treatment as occurring in only 25 % of patients.
Figs 1 and 2 show results in patients after operative hypophysectomy; three failed to show tumour regression and although growth hormone levels might suggest a successful operation, it can be seen that prolactin levels rose again; five had good tumour regression in keeping with the abolition of measurable prolactin. (Dr A R Boyns of the Tenovus Institute, Cardiff, measured the hormone levels.)
This new approach of directly assessing, by in vitro tissue survival, the hormone dependence of the individual's breast cancer seems to offer a fair guide to the clinical responsiveness to antihormonal measures (to date 28 of 29 predictions have been correct on follow up). It may enable us to select the third of patients who might respond to a good hypophysectomy or indeed suppression of prolactin levels by 2-Br-a-ergocryptine. The importance of monitoring prolactin levels during such treatments has been demonstrated.
